News

REIG JOFRE invoiced € 115M in the first quarter of 2020, with a growth in sales of 25% and an EBITDA of € 13M, 40% above the 2019 figure. The strong growth rate of 1Q20 is maintained at 26%.

• Notable growth in Pharmaceutical Technologies, +14%, impact of new acquisition in Specialty Pharmacare, +82% and good performance in Consumer Healthcare, + 4%
• The growth reflects the revenue from the new Osteoarticular business acquired in July 2019
• The second quarter has included the impact of the sales of essential drugs linked to the COVID 19 crisis, while certain ranges of prescription drugs have been affected by a slowdown in growth and the interruption of medical visits.
• Profitability on sales has evolved positively, thanks to the containment of operating expenses.
• EBITDA stands at 11% over sales, and registered a growth of 40% compared to the first half of the previous year.
• Investments continue at the expected level, with the main volume associated with the construction of the new Injectables Plant in Barcelona.
• The debt/EBITDA ratio has remained at the levels registered at the close of 2019 and currently stands at 2.7

Download the full document (PDF)